HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 10, September 2017 – Cardiovascular diseases       » Test strips for cancer detection get upgraded with nanoparticle bling       » Smart nano-pesticide to combat soil and water contamination       » China plans to launch "brain project" by year end       » UNAIDS encourages Chinese to produce drugs for Africa       » Korea-Singapore Healthcare Incubator to support Korean firms in Singapore and Southeast Asia       » Nanomaterial wrap for improved tissue imaging      
EYE ON CHINA
to-BBB and Sihuan enter into collaboration agreement

To-BBB, a brain drug development company, is entering into a collaboration agreement with Sun Moral International (HK) Limited, a wholly-owned subsidiary of Sihuan Pharmaceutical Holdings Group Limited. The agreement aims at the collaborative research and development of innovative drugs for Central Nervous System (CNS) diseases.

to-BBB and Sihuan will conduct feasibility studies by applying to-BBB's G-Technology®, a patented brain drug delivery technology for sustained release and enhanced brain delivery, to certain drug compounds owned by Sihuan. Based on the successful completion of the feasibility studies, both parties desire to enter into a commercial license agreement for collaborative development of one or more drug compounds using to-BBB's G-Technology.

Sihuan shall pursue the approval of the developed products in China. "Sihuan entered into the collaboration agreement with the aim to tap the high unmet medical need of drug products with sustained delivery to the CNS," says Dr. Che FengSheng, CEO and Chairman of Sihuan. "The collaboration will combine the research efforts of to-BBB's brain targeting technology and Sihuan's R&D resources in oncology and CNS. The R&D program will be overseen by a joint steering committee with representatives from to-BBB and Sihuan. The two parties will share the achievements of the R&D project."

"We are pleased by Sihuan's recognition that the G-Technology offers the safest possibility to enhance the delivery of drugs across the blood-brain barrier, aiming at therapeutic approaches for treating devastating CNS diseases," says Dr. Pieter Gaillard, CSO of to-BBB. "This unique approach has obtained multiple pre-clinical and clinical validations, including the development of to-BBB's lead product 2B3-101 for brain cancer that is currently in a Phase IIa trial."

Click here for the complete issue.

NEWS CRUNCH  
news $1.7 million awarded to Australian biomedical researchers through philanthropic Ramaciotti Foundations
news Genetically boosting the nutritional value of corn could benefit millions
news Inhibitor Pariet obtained approval of additional dosage in Japan for maintenance therapy of proton pump inhibitor resistant reflux esophagitis
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Infectious Diseases
October:
A change of heart — Cardiovascular diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy